Asked by: Patrick Grady (Scottish National Party - Glasgow North)
Question to the Foreign, Commonwealth & Development Office:
To ask the Minister of State, Foreign, Commonwealth and Development Office, what recent steps his Department has taken with the United Nations to help tackle (a) drug-resistant tuberculosis and (b) antimicrobial resistance.
Answered by Andrew Mitchell - Minister of State (Foreign, Commonwealth and Development Office) (Minister for Development)
The department actively contributed to the High Level Meeting on Tuberculosis held at the UN General Assembly last September, at which Lord Ahmad represented the UK. The UK's current £1billion commitment to the Global Fund to Fight AIDS, Tuberculosis and Malaria will support treatment for 41,800 people with Multi-Drug Resistant TB.
The UK funds major programmes and research to tackle Antimicrobial Resistance (AMR), and strengthen health, water, sanitation, and hygiene systems. The High-Level Meeting on AMR is an excellent opportunity to catalyse global progress, set high ambitions across the One Health spectrum, and promote equitable access to and stewardship of antimicrobials.
Asked by: David Mundell (Conservative - Dumfriesshire, Clydesdale and Tweeddale)
Question to the Foreign, Commonwealth & Development Office:
To ask the Minister of State, Foreign, Commonwealth and Development Office, what assessment his Department has made of the effectiveness of the Robert Carr Fund in advancing human rights of inadequately served populations.
Answered by Andrew Mitchell - Minister of State (Foreign, Commonwealth and Development Office) (Minister for Development)
The UK is proud to be a long-term funder of the Robert Carr Fund (RCF), we consider it to be a very effective mechanism that supports the leadership, priorities and rights of some of the most marginalised people, in order to expand their access to the HIV, SRHR and health services they need.
Robert Carr is the world's leading international fund focused on funding global and regional networks led by, involving, and serving people who face a higher HIV risk than the general population, systematic human rights violations, and barriers to information and HIV and SRH services.
Working with community-led and grassroots organisations is key to achieving the targets in the Global AIDS Strategy. Our investment into the Robert Carr Fund, along with other organisations such as the Global Fund and UNAIDS, is important in helping countries to implement actions and make progress towards targets under the Strategy.
Asked by: David Mundell (Conservative - Dumfriesshire, Clydesdale and Tweeddale)
Question to the Foreign, Commonwealth & Development Office:
To ask the Minister of State, Foreign, Commonwealth and Development Office, what assessment his Department has made of the potential merits of funding the Robert Carr Fund to support the achievement of the targets in the UNAIDS Global AIDS Strategy 2024-27.
Answered by Andrew Mitchell - Minister of State (Foreign, Commonwealth and Development Office) (Minister for Development)
The UK is proud to be a long-term funder of the Robert Carr Fund (RCF), we consider it to be a very effective mechanism that supports the leadership, priorities and rights of some of the most marginalised people, in order to expand their access to the HIV, SRHR and health services they need.
Robert Carr is the world's leading international fund focused on funding global and regional networks led by, involving, and serving people who face a higher HIV risk than the general population, systematic human rights violations, and barriers to information and HIV and SRH services.
Working with community-led and grassroots organisations is key to achieving the targets in the Global AIDS Strategy. Our investment into the Robert Carr Fund, along with other organisations such as the Global Fund and UNAIDS, is important in helping countries to implement actions and make progress towards targets under the Strategy.
Asked by: David Mundell (Conservative - Dumfriesshire, Clydesdale and Tweeddale)
Question to the Foreign, Commonwealth & Development Office:
To ask the Minister of State, Foreign, Commonwealth and Development Office, what assessment his Department has made of the effectiveness of the Robert Carr Fund in advancing HIV and health outcomes for inadequately served populations.
Answered by Andrew Mitchell - Minister of State (Foreign, Commonwealth and Development Office) (Minister for Development)
The UK is proud to be a long-term funder of the Robert Carr Fund (RCF), we consider it to be a very effective mechanism that supports the leadership, priorities and rights of some of the most marginalised people, in order to expand their access to the HIV, SRHR and health services they need.
Robert Carr is the world's leading international fund focused on funding global and regional networks led by, involving, and serving people who face a higher HIV risk than the general population, systematic human rights violations, and barriers to information and HIV and SRH services.
Working with community-led and grassroots organisations is key to achieving the targets in the Global AIDS Strategy. Our investment into the Robert Carr Fund, along with other organisations such as the Global Fund and UNAIDS, is important in helping countries to implement actions and make progress towards targets under the Strategy.
Asked by: Matt Western (Labour - Warwick and Leamington)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking to ensure people with diabetes can continue to access the insulin they need.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
We are aware of supply issues with some insulin products, however the vast majority are in stock. Comprehensive management guidance on alternative products has been issued to the National Health Service where needed.
The medicine supply chain is highly regulated, complex, and global. Supply disruption is an issue which affects the United Kingdom, as well as the other countries around the world, and it can have a variety of causes, including manufacturing issues, problems with access to raw ingredients, and sudden spikes in demand.
There is a team within the Department that deals specifically with medicine supply problems. It has well-established tools and processes to manage medicine supply issues, working closely with the Medicines and Healthcare products Regulatory Agency, the pharmaceutical industry, NHS England, and others operating in the supply chain, to help prevent shortages and expedite resupply as soon as possible, to ensure that the risks to patients are minimised.
Asked by: Gen Kitchen (Labour - Wellingborough)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she plans to enable the provision of additional services in GP surgeries in Wellingborough constituency.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
All practices can opt in to providing Enhanced Services, as well as Direct Enhanced Services for which practices are paid separately from the global sum payment. Integrated care boards, as commissioners of primary care, are responsible for commissioning Local Enhanced Services, which vary in scope and funding to fit the needs of local areas.
Asked by: Earl of Dundee (Conservative - Excepted Hereditary)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what incentives they are offering to medical partnerships to assist type two diabetes sufferers through research into both stem-cell and non-stem-cell treatments for diabetes type one sufferers.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is delivering improvements as part of the Vision for the Future of UK Clinical Research Delivery to make the United Kingdom a world leader in clinical research, attracting investment from commercial companies to deliver cutting edge research in a range of disease areas, including diabetes. For example, we introduced the National Contract Value Review to standardise costing and contracting for commercial research in the National Health Service.
This has reduced set up times for clinical research by a third which makes running research in the UK more efficient for commercial companies.
The National Institute for Health and Care Research’s (NIHR) Clinical Research Network (CRN) supports conduct of clinical research in the NHS, providing tailored support for both non-commercial organisations and the life sciences industry. The CRN has a Diabetes Speciality Group to support research across key priorities in diabetes.
The NIHR works in partnership with Diabetes UK to deliver the joint UK Strategy for Clinical and Applied Diabetes Research. The NIHR also funds a Global Health Research Unit on Diabetes and Cardiovascular Disease in South Asia, creating partnerships between research organisations in Bangladesh, India, Pakistan, Sri Lanka and the UK.
Asked by: Earl of Dundee (Conservative - Excepted Hereditary)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what incentives they are offering to commercial operators to form medical partnerships to advance stem-cell and non-stem-cell treatments for diabetes type one sufferers.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is delivering improvements as part of the Vision for the Future of UK Clinical Research Delivery to make the United Kingdom a world leader in clinical research, attracting investment from commercial companies to deliver cutting edge research in a range of disease areas, including diabetes. For example, we introduced the National Contract Value Review to standardise costing and contracting for commercial research in the National Health Service.
This has reduced set up times for clinical research by a third which makes running research in the UK more efficient for commercial companies.
The National Institute for Health and Care Research’s (NIHR) Clinical Research Network (CRN) supports conduct of clinical research in the NHS, providing tailored support for both non-commercial organisations and the life sciences industry. The CRN has a Diabetes Speciality Group to support research across key priorities in diabetes.
The NIHR works in partnership with Diabetes UK to deliver the joint UK Strategy for Clinical and Applied Diabetes Research. The NIHR also funds a Global Health Research Unit on Diabetes and Cardiovascular Disease in South Asia, creating partnerships between research organisations in Bangladesh, India, Pakistan, Sri Lanka and the UK.
Asked by: Earl of Dundee (Conservative - Excepted Hereditary)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what steps they are taking to promote international cooperation and joint research to find solutions for both type one and type two diabetes sufferers.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is delivering improvements as part of the Vision for the Future of UK Clinical Research Delivery to make the United Kingdom a world leader in clinical research, attracting investment from commercial companies to deliver cutting edge research in a range of disease areas, including diabetes. For example, we introduced the National Contract Value Review to standardise costing and contracting for commercial research in the National Health Service.
This has reduced set up times for clinical research by a third which makes running research in the UK more efficient for commercial companies.
The National Institute for Health and Care Research’s (NIHR) Clinical Research Network (CRN) supports conduct of clinical research in the NHS, providing tailored support for both non-commercial organisations and the life sciences industry. The CRN has a Diabetes Speciality Group to support research across key priorities in diabetes.
The NIHR works in partnership with Diabetes UK to deliver the joint UK Strategy for Clinical and Applied Diabetes Research. The NIHR also funds a Global Health Research Unit on Diabetes and Cardiovascular Disease in South Asia, creating partnerships between research organisations in Bangladesh, India, Pakistan, Sri Lanka and the UK.
Asked by: Earl of Dundee (Conservative - Excepted Hereditary)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what partnerships and expedients they are encouraging to progress diabetes type one stem cell and non-stem-cell research.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is delivering improvements as part of the Vision for the Future of UK Clinical Research Delivery to make the United Kingdom a world leader in clinical research, attracting investment from commercial companies to deliver cutting edge research in a range of disease areas, including diabetes. For example, we introduced the National Contract Value Review to standardise costing and contracting for commercial research in the National Health Service.
This has reduced set up times for clinical research by a third which makes running research in the UK more efficient for commercial companies.
The National Institute for Health and Care Research’s (NIHR) Clinical Research Network (CRN) supports conduct of clinical research in the NHS, providing tailored support for both non-commercial organisations and the life sciences industry. The CRN has a Diabetes Speciality Group to support research across key priorities in diabetes.
The NIHR works in partnership with Diabetes UK to deliver the joint UK Strategy for Clinical and Applied Diabetes Research. The NIHR also funds a Global Health Research Unit on Diabetes and Cardiovascular Disease in South Asia, creating partnerships between research organisations in Bangladesh, India, Pakistan, Sri Lanka and the UK.